Bilateral theta burst stimulation noninferior to standard bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Sept. 28, 2022 (HealthDay News) — Bilateral theta burst stimulation (TBS) is noninferior to standard bilateral repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression in older adults, according to a study published online Sept. 21 in JAMA Psychiatry<\/em>.<\/p>\n Daniel M. Blumberger, M.D., from the Temerty Centre for Therapeutic Brain Intervention at the University of Toronto, and colleagues conducted a randomized noninferiority trial to examine the effectiveness and tolerability of TBS (85 patients) versus standard rTMS (87 patients; four to six weeks of bilateral treatment) in older adults (mean age, 67.1 years) with treatment-resistant depression. <\/p>\n The researchers found that mean Montgomery- \u0085sberg Depression Rating Scale total scores improved from 25.6 to 17.3 for rTMS and 25.7 to 15.8 for TBS (adjusted difference, 1.55), establishing noninferiority for TBS. All-cause dropout rates were similar between the groups (2.3 and 7.1 percent for rTMS and TBS, respectively).<\/p>\n “To our knowledge, we report on the largest randomized clinical trial of nonconvulsive neuromodulation in older adults with treatment-resistant depression. For these patients, our findings provide strong evidence that TBS is noninferior to standard rTMS in reducing depressive symptoms,” the authors write. “Using TBS rather than rTMS could increase access to treatment several-fold for older adults with treatment-resistant depression.”<\/p>\n Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n